

## Format for ANSWERING REVIEWERS

August 28, 2014

Dear Editors,



Please find enclosed the edited manuscript in Word format (file name: Hyperoxaluria revised manuscript)

**Title:** Primary and Secondary Hyperoxaluria: Understanding the enigma

**Author:** Bhavna Bhasin, Hatice Melda Ürekli, Mohamed G Atta

**ESPS Manuscript NO:** 12744

Dear Editors:

We would like to thank you and all the reviewers for their valuable comments on this review paper. We revised our manuscript according to the thoughtful input from the peer-review process. We have provided a point-by-point response to the reviewers' comments below and highlighted the changes in the manuscript. We have hope that you will view our revised manuscript favorably.

Sincerely,

Bhavna Bhasin, MD

**Reviewer #1:1. Quite a long and detailed review on the subject. It should be shortened for readers' attention.**

**Response:** We believe that the manuscript is designed to be a comprehensive review and should not be shortened since it can be used as a reference for the interested reader.

**Reviewer #2: In this manuscript, the authors reviewed the primary and secondary hyperoxaluria with the literature available to date. However, I have the following comments which need to be addressed before publication.**

1. **Abstract: "Definitive diagnosis of primary hyperoxaluria is achieved by genetic studies and liver biopsy, if genetic studies are inconclusive." - this statement is not clear**

**Response:** We have revised this statement which now appears as:

*"Definitive diagnosis of primary hyperoxaluria is achieved by genetic studies and if genetic studies prove inconclusive, liver biopsy is undertaken to establish diagnosis."*

2. **Abstract: "We also have limited knowledge of role of transplantation in secondary hyperoxaluria"- This statement is unrelated and needs to be removed**

**Response:** We have deleted this statement from the abstract.

3. **Page 8: This form of hyperoxaluria is seen in partial gastrectomy, bariatric surgery, jejunoileal bypass, and inflammatory bowel disease. - give a reference for this statement.**

**Response:** We have added the appropriate references

4. **Page 12-13: "In PH patients with ESRD, plasma oxalate levels is typically higher than 80  $\mu\text{mol/L}$  while in non PH hyperoxaluric patients, the plasma oxalate level may range between 30-80  $\mu\text{mol/L}$ ." Along with this statement, the authors are requested to include the plasma oxalate levels for normal non stone forming subjects.**

**Response:** We have added the plasma oxalate levels in normal subjects and this line now reads as:

*"This is in contrast to plasma oxalate levels of 1-5  $\mu\text{mol/L}$  in normal subjects."*

5. **1.73 m<sup>2</sup> was used throughout the manuscript. Please describe how you will arrive at 1.73 m<sup>2</sup> and also state the reference. This will help readers to understand without going back to reference.**

**Response:** We have added an additional statement and reference to explain this on page 12, para 2, line 1. This line now reads as:

*“The initial biochemical tests include urinary oxalate excretion preferably measured in 24 hour urine collection and adjustment of the oxalate excretion per 1.73 m<sup>2</sup> of the body surface area is recommended.”*

**Reviewer #3: 1. In abstract section on diagnostic tools, I recommend to exclude the PCR test to detect Oxalobacter formigenes in the stool. Since the diagnostic accuracy of this test has not been generally substantiated**

**Response:** We have deleted this line from the abstract.

**2. In the treatment measure authors should further elaborate as to why the intestinal absorption of oxalate is limited in patients with PH.**

**Response:** We have added an explanation for this effect along with the appropriate reference and this line now reads as:

*“In a study by Sikora et al, intestinal absorption of oxalate in patients with PH was noted to be less than 7%. This was attributed to less absorption and translocation of the SLC26A6 transporters favoring oxalate secretion over absorption(78).”*

**Dr. Mohamed Atta, MD**

Division of Nephrology  
Johns Hopkins University  
1830 E. Monument Street, Suite 416, Baltimore  
MD 21287, United States  
matta1@jhmi.edu